US equities
|
MU
$1,097.39
▲+3.03%
NVDA
$230.86
▲+1.09%
SNDK
$1,787.69
▲+2.75%
INTC
$120.00
▼-0.19%
AAPL
$330.32
▼-0.81%
GOOGL
$338.24
▼-1.70%
TSLA
$354.11
▼-0.20%
AMD
$615.73
▲+0.65%
MU
$1,097.39
▲+3.03%
NVDA
$230.86
▲+1.09%
SNDK
$1,787.69
▲+2.75%
INTC
$120.00
▼-0.19%
AAPL
$330.32
▼-0.81%
GOOGL
$338.24
▼-1.70%
TSLA
$354.11
▼-0.20%
AMD
$615.73
▲+0.65%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Telomir Pharmaceuticals, Inc. - Common Stock
(NQ:
TELO
)
1.170
-0.030 (-2.50%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Telomir Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Telomir-Zn Improvements in Visual Function and Retinal Structure in AMD Model
September 17, 2026
Via
Investor Brand Network
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
September 17, 2026
Findings Strengthen Telomir-Zn’s Oncology-Focused Platform While Demonstrating Broader Relevance of Its Metal-Dependent Epigenetic Biology
From
Telomir Pharmaceuticals, Inc.
Via
GlobeNewswire
NetworkNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Telomir-Zn Growth Inhibition Across Human and Canine Osteosarcoma Models
September 14, 2026
Via
Investor Brand Network
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
September 14, 2026
Preclinical Findings Support Parallel Development Pathway in Canine Osteosarcoma as TNBC Program Advances Toward Site Initiation
From
Telomir Pharmaceuticals, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Peer-Reviewed Telomir-Zn Data Supporting Phase 1/2 TNBC Program
August 10, 2026
Via
Investor Brand Network
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
August 10, 2026
Iron-Rescue Experiments Confirm Iron-Dependent Mechanism. Tumor Suppressor Gene Reactivation and Anti-Tumor and Anti-Metastatic Activity Across Multiple Models.
From
Telomir Pharmaceuticals, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Publishes Preclinical Data Showing Improved Insulin Sensitivity in Type 2 Diabetes Model
June 15, 2026
Via
Investor Brand Network
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
June 15, 2026
Via
ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Peer-Reviewed Preclinical Data Supporting Telomir-Zn in Wilson’s Disease
May 20, 2026
Via
Investor Brand Network
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
May 20, 2026
Via
ACCESS Newswire
BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Receives FDA IND Clearance for Telomir-Zn in Triple-Negative Breast Cancer
April 30, 2026
Via
Investor Brand Network
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
April 30, 2026
Via
ACCESS Newswire
MissionIRNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Closes TELI Acquisition, Secures Global Rights to Telomir-1
April 24, 2026
Via
Investor Brand Network
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
April 24, 2026
Via
ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Submits IND for TNBC Candidate Telomir-1
March 31, 2026
Via
Investor Brand Network
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
March 31, 2026
Via
ACCESS Newswire
BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Iron-Dependent Tumor Cell Mortality in TNBC Models
February 17, 2026
Via
Investor Brand Network
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
February 17, 2026
Via
ACCESS Newswire
BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports New Cellular Data Demonstrating Coordinated Intracellular Zinc Increase and Iron Reduction With Telomir-Zn
February 05, 2026
Via
Investor Brand Network
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
February 05, 2026
Via
ACCESS Newswire
MissionIRNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Positive Telomir-1 Results In TNBC Zebrafish Xenograft Study
January 05, 2026
Via
Investor Brand Network
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
January 05, 2026
Via
ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Favorable IND-Enabling GLP Safety Results for Telomir-1
December 18, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
December 18, 2025
Via
ACCESS Newswire
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
November 25, 2025
Via
ACCESS Newswire
TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death
↗
November 21, 2025
HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity in this aggressive human model, the company said.
Via
Stocktwits
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
November 21, 2025
Via
ACCESS Newswire
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
November 12, 2025
Via
ACCESS Newswire
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
October 23, 2025
Via
ACCESS Newswire
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth
October 21, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
Next >
